ReviewFrontiers in cellular and infection microbiology2020
Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections.
Review in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 76 citations in OpenAlex.
- Integrating silver nanomaterials in wound healing: from physicochemical properties to clinical translation.Journal of nanobiotechnology · 2026Review
- Paracoccidioidomycosis in the 21st century: Challenges and milestones.PLoS neglected tropical diseases · 2026Review
- Direct Inoculation of Pathogenic Yeasts into Mouse Lung by Trans-tracheal Instillation.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Nitric Oxide-Releasing Microparticles: A Novel Treatment for Onychomycosis.Molecular pharmaceutics · 2025Article
- In vivo and in vitro pathogenicity of Fusarium oxysporum and its biofilm components.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Regulation of Ergosterol Biosynthesis in Pathogenic Fungi: Opportunities for Therapeutic Development.Microorganisms · 2025Review
- Novel Strategies for Preventing Fungal Infections-Outline.Pathogens (Basel, Switzerland) · 2025Review
- Advancing cryptococcal treatment: The role of nanoparticles in mitigating antifungal resistance.Current research in microbial sciences · 2025Review
- Nanotechnology-powered Meningitis Therapies: Lipid Nanoparticles Lead the Way.Current pharmaceutical biotechnology · 2025Review
- Nanotechnology for fungal pathogen control in crops: innovations, public health impacts, and disease prevention.Frontiers in fungal biology · 2025Review
- Review
- Liposomal formulation of a new antifungal hybrid compound provides protection againstAntimicrobial agents and chemotherapy · 2024Article
- A tribute to a man of science: lessons from Professor Luiz R. Travassos (1938-2020).Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Review
- Micro- and nanoparticles as platforms for the treatment of fungal infections: present and future perspectives.Future microbiology · 2023Article
- Solid lipid nanoparticles, an effective carrier for classical antifungal drugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Review
- Targeting the P10 Peptide in Maturing Dendritic Cells via the DEC205 Receptor In Vivo: A New Therapeutic Strategy against Paracoccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2023Article
- The paradigm of prophylactic viral outbreaks measures by microbial biosurfactants.Journal of infection and public health · 2023Review
- Biodistribution and Adjuvant Effect of an Intranasal Vaccine Based on Chitosan Nanoparticles against Paracoccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2023Article
- Comparative Genomics ofJournal of fungi (Basel, Switzerland) · 2023Article
- Targeting of phagolysosomes containing conidia of the fungus Aspergillus fumigatus with polymeric particles.Applied microbiology and biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment modalities for systemic mycoses are still limited. Currently, the main antifungal therapeutics include polyenes, azoles, and echinocandins. However, even in the setting of appropriate administration of antifungals, mortality rates remain unacceptably high. Moreover, antifungal therapy is expensive, treatment periods can range from weeks to years, and toxicity is also a serious concern. In recent years, the increased number of immunocompromised individuals has contributed to the high global incidence of systemic fungal infections. Given the high morbidity and mortality rates, the complexity of treatment strategies, drug toxicity, and the worldwide burden of disease, there is a need for new and efficient therapeutic means to combat invasive mycoses. One promising avenue that is actively being pursued is nanotechnology, to develop new antifungal therapies and efficient vaccines, since it allows for a targeted delivery of drugs and antigens, which can reduce toxicity and treatment costs. The goal of this review is to discuss studies using nanoparticles to develop new therapeutic options, including vaccination methods, to combat systemic mycoses caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.